BioXcel Therapeutics annual gross margin
2022
2023
2024
2025
BioXcel Therapeutics Gross Margin Growth & History (BTAI)
BioXcel Therapeutics's gross margin was 74.45% for fiscal 2025.
View full BioXcel Therapeutics company overviewBioXcel Therapeutics annual gross margin history
| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 74.45% | +69.03 pp |
| 2024 | 2024-12-31 | 5.43% | −3.27 pp |
| 2023 | 2023-12-31 | 8.70% | −85.97 pp |
| 2022 | 2022-12-31 | 94.67% | — |
BioXcel Therapeutics quarterly gross margin
Q3.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 87.91% | +77.08 pp |
| Q1 2026 | 2026-03-31 | −37.38% | −129.05 pp |
| Q4 2025 | 2025-12-31 | 87.50% | +214.55 pp |
| Q3 2025 | 2025-09-30 | 88.78% | +535.50 pp |
| Q2 2025 | 2025-06-30 | 10.83% | −83.55 pp |
| Q1 2025 | 2025-03-31 | 91.67% | +5.41 pp |
| Q4 2024 | 2024-12-31 | −127.05% | −37.42 pp |
| Q3 2024 | 2024-09-30 | −446.73% | −396.58 pp |
| Q2 2024 | 2024-06-30 | 94.38% | +0.07 pp |
| Q1 2024 | 2024-03-31 | 86.25% | −9.38 pp |
| Q4 2023 | 2023-12-31 | −89.63% | — |
| Q3 2023 | 2023-09-30 | −50.15% | −142.12 pp |
| Q2 2023 | 2023-06-30 | 94.31% | — |
| Q1 2023 | 2023-03-31 | 95.63% | — |
| Q3 2022 | 2022-09-30 | 91.97% | — |
BioXcel Therapeutics gross margin trends
Between the periods ended 2022-12-31 and 2025-12-31, BioXcel Therapeutics's gross margin decreased from 94.67% to 74.45%, a change of −20.21 percentage points. The latest reported quarter, Q2 2026, shows 87.91%.
About the metric
What gross margin means
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
Calculation and source
How gross margin is calculated
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BioXcel Therapeutics source filings ↗